Pan‐cancer population pharmacokinetics and exposure‐safety and ‐efficacy analyses of atezolizumab in patients with high tumor mutational burden

• Main Authors: Colby S. Shemesh (Author), Phyllis Chan (Author), Fatema A. Legrand (Author), David S. Shames (Author), Meghna Das Thakur (Author), Jane Shi (Author), Lorna Bailey (Author), Shweta Vadhavkar (Author), Xian He (Author), Wei Zhang (Author), René Bruno (Author)
• Format: Book
• Published: Wiley, 2020-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract We retrospectively investigated the pharmacokinetics and exposure‐efficacy/safety relationships of single‐agent atezolizumab based on tissue tumor mutational burden (tTMB) status (high vs low [≥16 vs <16 mutations/megabase]) in a pan‐tumor population from seven clinical trials. Data sour...